Zipalertinib clinical trials
Also written CLN-081 and TAS6417.
How each study uses zipalertinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zipalertinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2023 (2); 1 more planned to start later
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2023 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
Taiho Oncology, Inc. (3) · Cullinan Therapeutics Inc. (1) · Stanford University (1) · Jonsson Comprehensive Cancer Center (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test zipalertinib, phase 3 first.
- May 2027REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)Phase 3 · Taiho Oncology, Inc.
Studies
Open first, then newest update. How each study uses zipalertinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionRecruitingPhase 3Taiho Oncology, Inc.NCT07128199Written as TAS6417
- A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.RecruitingPhase 2Taiho Oncology, Inc.NCT05967689Written as TAS6417
- Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLCNot yet recruitingPhase 2Stanford UniversityNCT07802834Written as Zipalertinib
- Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung CancerNot yet recruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07229339Written as Zipalertinib
- REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)Active, not recruitingPhase 3Taiho Oncology, Inc.NCT05973773Written as TAS6417
- A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung CancerActive, not recruitingPhase 1/2Cullinan Therapeutics Inc.NCT04036682Written as CLN-081
Codes
What other systems call zipalertinib · ClinicalTrials.gg INT001382
- MeSH (NLM) C000709247zipalertinibOne source ClinicalTrials.gov
- UNII (FDA) T4YMU8TW9HZIPALERTINIBOne source FDA
- NCI Thesaurus C165567ZipalertinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000709247 | zipalertinib | One source ClinicalTrials.gov |
| UNII (FDA) | T4YMU8TW9H | ZIPALERTINIB | One source FDA |
| NCI Thesaurus | C165567 | Zipalertinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.